Blogs

Gastrointestinal cancer - ASCO18
Abstract 4011: A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal junction cancer refractory to trastuzumab (Herceptin) combined with fluoropyrimidine and platinum: WJOG7112G. Conclusion: Continuation of trastuzumab beyond progression (TMB Strategy) in this patient population was not found to have the Continue Reading
 Categories : ASCO18, Oncology Posted by Sakshi Saini  , , , , ,
Breast cancer - ASCO18
Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Conclusion: Trastuzumab’s known side effects include a risk for heart problems. The women who had Continue Reading
 Categories : ASCO18, Oncology Posted by Sakshi Saini  
oxford_global
Last week London had a pretty good weather, slightly chilly evenings and surprisingly, sun-kissed mornings! Yes, we were there to attend the 5th Biennial Biosimilars & Biobetters Congress in London (since the event was in London. I guess it’s a mandate to start with a weather update J) It was Continue Reading
 Categories : Biosimilars, Conference Coverage Posted by Preeti Parikh  ,
clinical_dev_biosimilar
As the regulatory frameworks for biosimilar development are evolving in both US and EU, more and more biosimilar developers are entering the competitive landscape. Many commercially successful Oncology biologics are going off-patent in next few years, presenting a lucrative opportunity for biosimilar development. The biosimilars pertaining to these biologics constitute Continue Reading
 Categories : Biosimilars, Disease Area Strategy, Oncology Posted by Richa Agrawal  
Biosimilar dev in US and EU
As per the 2015 IMS report, the global biologics market is projected to reach 28% of the global pharmaceuticals market by 2020 [1]. This would translate to the biologics market potentially worth USD 390 billion in 2020. As many of the biologics will face patent expiration in the next 5 Continue Reading
 Categories : Biosimilars, Disease Area Strategy Posted by Richa Agrawal